Myriad Genetics Upgraded to Market Perform at JMP Securities (MYGN)
Myriad Genetics (NASDAQ:MYGN) was upgraded by analysts at JMP Securities from an “underperform” rating to a “market perform” rating in a research report issued to clients and investors on Wednesday, TheFlyOnTheWall.com reports. The firm currently has a $30.80 target price on the stock. JMP Securities’ price target points to a potential upside of 13.32% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Mizuho raised their price target on shares of Myriad Genetics from $24.00 to $28.00 in a research note to investors on Wednesday. They now have a “neutral” rating on the stock. Separately, analysts at Bank of America Corp. reiterated a “neutral” rating on shares of Myriad Genetics in a research note to investors on Tuesday, December 31st. They now have a $25.00 price target on the stock, down previously from $31.00. Finally, analysts at Goldman Sachs Group Inc. cut their price target on shares of Myriad Genetics from $32.00 to $20.00 in a research note to investors on Monday, December 30th. They now have a “hold” rating on the stock. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $27.27.
Myriad Genetics (NASDAQ:MYGN) traded up 11.55% during mid-day trading on Wednesday, hitting $30.32. 5,642,230 shares of the company’s stock traded hands. Myriad Genetics has a one year low of $20.02 and a one year high of $38.27. The stock’s 50-day moving average is $24.18 and its 200-day moving average is $26.12. The company has a market cap of $2.267 billion and a P/E ratio of 13.02.
Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings data on Tuesday, February 4th. The company reported $0.66 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.46 by $0.20. The company had revenue of $204.06 million for the quarter, compared to the consensus estimate of $176.02 million. During the same quarter in the prior year, the company posted $0.42 earnings per share. The company’s quarterly revenue was up 36.9% on a year-over-year basis. On average, analysts predict that Myriad Genetics will post $1.97 earnings per share for the current fiscal year.
Myriad Genetics, Inc (NASDAQ:MYGN) is a molecular diagnostic company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.